These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Direct Targeting of Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073 [TBL] [Abstract][Full Text] [Related]
5. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype. Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365 [TBL] [Abstract][Full Text] [Related]
6. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status. Currò M; Ferlazzo N; Giunta ML; Montalto AS; Russo T; Arena S; Impellizzeri P; Caccamo D; Romeo C; Ientile R Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085516 [TBL] [Abstract][Full Text] [Related]
8. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804 [TBL] [Abstract][Full Text] [Related]
9. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Marrano P; Irwin MS; Thorner PS Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929 [TBL] [Abstract][Full Text] [Related]
12. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
13. Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification. Mitchell CB; O'Neill GM Cell Adh Migr; 2017 Jan; 11(1):68-79. PubMed ID: 27224546 [TBL] [Abstract][Full Text] [Related]
14. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620 [TBL] [Abstract][Full Text] [Related]
15. MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature. Langenberg-Ververgaert KPS; Renzi S; Chung CT; Shago M; Lo W; Davidson S; Villani A; Baruchel S; Irwin MS; Morgenstern DA J Pediatr Hematol Oncol; 2019 Jul; 41(5):388-391. PubMed ID: 31094905 [TBL] [Abstract][Full Text] [Related]
16. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149 [TBL] [Abstract][Full Text] [Related]
17. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367 [TBL] [Abstract][Full Text] [Related]
18. MYC regulates metabolism through vesicular transfer of glycolytic kinases. Tsakaneli A; Carregari VC; Morini M; Eva A; Cangemi G; Chayka O; Makarov E; Bibbò S; Capone E; Sala G; De Laurenzi V; Poon E; Chesler L; Pieroni L; Larsen MR; Palmisano G; Sala A Open Biol; 2021 Dec; 11(12):210276. PubMed ID: 34847775 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Alaminos M; Gerald WL; Cheung NK Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351 [TBL] [Abstract][Full Text] [Related]
20. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]